Botify Launches Botify Activation to Accelerate Speed to Market and Content Discoverability for the World’s Most Ambitious Brands
Botify, a leading performance marketing platform for organic search, today announced the launch of Botify Activation to empower organizations to regain control of how search engines and consumers find products and services organically online.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005318/en/
A key suite within the Botify Platform, which already includes Botify Analytics and Botify Intelligence, Botify Activation connects insights about a website’s performance with making brands more discoverable online. By enabling scalable, automated site improvements and content discoverability, Botify Activation provides brands with the ability to expedite how search engines discover and interpret website pages—improving speed to market while also boosting efficiency across teams.
Specifically, Botify Activation is comprised of the following solutions:
- SpeedWorkers: Serves fully-rendered pages to search engines, ensuring more content can be crawled, indexed, and ultimately found to drive traffic and revenue
- PageWorkers: Automation capabilities that allow brands to make organic search changes to their website quickly and at scale
- FastIndex: Easily generate optimized sitemaps to ensure that search engines prioritize the most critical content on your website
"Botify Activation has given us confidence that our strategic pages – ones that drive sales critical to our business – are being found by search engines and by potential buyers. We’ve seen substantial growth in revenue tied to these product pages, which is crucial during the holiday season and throughout the rest of the year,” said Dave Han, VP of Product, Neiman Marcus Group.
Remaining in control of how consumers find content through organic search results, by ensuring search engines can see a brand’s most valuable content, is vital in today’s digital age. In fact, a recent survey conducted by Botify shared that one third of both U.S. and U.K. searchers said they would change their search terms if they were not satisfied with the initial results, as opposed to clicking through multiple results pages.
Botify Activation ensures that consumers find brands’ most relevant and strategic website pages during the initial search, creating touchpoints to maximize online revenue and reduce missed opportunities to connect with potential customers.
“We can rapidly respond to seasonal opportunities on our website quickly with Botify Activation as it enables us to make organic search optimizations at scale, without the need for dev resources. We were able to insert the most relevant Black Friday dynamic keywords across all our product pages in minutes using Botify Activation. Without it, those optimizations would have taken months to be implemented,” said Wayne Burden, Global Head of SEO, Ecco.
Further, in the same survey, more than half of U.S. and U.K. respondents reported that they sometimes follow or convert to a new brand when finding one through search. This demonstrates that meeting consumers at the right moment on their search journey is essential to establishing and building trust—impacting bottom line and future revenue.
“With the current economic uncertainty, companies are forced to do more with less to generate higher profitability. Botify Activation addresses this challenge by empowering search professionals to automatically make website improvements to ensure the utmost visibility,” said Adrien Menard, CEO of Botify. “With optimizations now made within minutes instead of months, for every $1 invested in Botify Activation, they can generate 3x more return than with traditional advertising campaigns.”
Read more about Botify Activation.
About Botify
Botify, a leading performance marketing platform for organic search, strengthens the digital brand experience by creating greater content findability. Using proprietary first-party data, Botify protects and scales organic web traffic by surfacing deeper insights and understanding behind hidden organic search ROI—offering intelligent opportunities to increase relevant search results, profitability and build better brand authority in parallel and at scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005318/en/
Contact information
Natasha Koleas
PAN Communications
949-397-7582
botify@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom